Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.13 and traded as low as $4.01. Aldeyra Therapeutics shares last traded at $4.13, with a volume of 3,379,053 shares changing hands.

Aldeyra Therapeutics Stock Performance

The company has a market cap of $248.54 million, a P/E ratio of -7.25 and a beta of 0.97. The stock’s fifty day moving average price is $4.98 and its two-hundred day moving average price is $5.13.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. On average, equities research analysts forecast that Aldeyra Therapeutics, Inc. will post -0.92 EPS for the current year.

Institutional Trading of Aldeyra Therapeutics

Several large investors have recently bought and sold shares of ALDX. AQR Capital Management LLC boosted its stake in shares of Aldeyra Therapeutics by 275.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock valued at $5,645,000 after purchasing an additional 1,081,257 shares in the last quarter. 683 Capital Management LLC lifted its stake in Aldeyra Therapeutics by 86.6% in the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after purchasing an additional 710,000 shares during the last quarter. Kennedy Capital Management LLC boosted its position in Aldeyra Therapeutics by 61.9% in the third quarter. Kennedy Capital Management LLC now owns 1,112,213 shares of the biotechnology company’s stock valued at $5,806,000 after buying an additional 425,245 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Aldeyra Therapeutics by 590.5% during the third quarter. Bank of America Corp DE now owns 390,078 shares of the biotechnology company’s stock worth $2,036,000 after buying an additional 333,587 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in shares of Aldeyra Therapeutics by 49.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 947,551 shares of the biotechnology company’s stock worth $4,946,000 after buying an additional 313,395 shares during the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.